| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
1 Tumor Immunology Program, Stanley S. Scott Cancer Center, and 2 Departments of Pathology and 3 Pediatrics, Louisiana State University, Health Sciences Center, New Orleans, Louisiana; 4 H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida; and 5 Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
chain and impairs T-cell responses. Using a 3LL murine lung carcinoma model we tested whether arginase I was produced in the tumor microenvironment and could decrease CD3 expression and impair T-cell function. The results show that a subpopulation of mature tumor-associated myeloid cells express high levels of arginase I, whereas tumor cells and infiltrating lymphocytes do not. Arginase I expression in the tumor was seen on day 7 after tumor injection. Tumor-associated myeloid cells also expressed high levels of cationic amino acid transporter 2B, which allowed them to rapidly incorporate L-Arginine (L-Arg) and deplete extracellular L-Arg in vitro. L-Arg depletion by tumor-associated myeloid cells blocked the re-expression of CD3 in stimulated T cells and inhibited antigen-specific proliferation of OT-1 and OT-2 cells. The injection of the arginase inhibitor N-hydroxy-nor-L-Arg blocked growth of s.c. 3LL lung carcinoma in mice. High levels of arginase I were also found in tumor samples of patients with non-small cell carcinoma. Therefore, arginase I production by mature myeloid cells in the tumor microenvironment may be a central mechanism for tumor evasion and may represent a target for new therapies. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
L-Arg is metabolized by arginase I, arginase II, and the inducible nitric oxide synthase (11)
. Arginase I and arginase II are encoded by two distinct genes and are located in the cytoplasm and mitochondria, respectively. Both enzymes hydrolyze L-Arg into urea and L-ornithine, the latter being the main substrate for the production of polyamines (putrescine, spermidine, and spermine) that are required for cell cycle progression. L-Arg can also be metabolized by inducible nitric oxide synthase to produce citrulline and nitric oxide, important in vascular homeostasis and cytotoxic mechanisms of macrophages (12)
. High arginase activity has been described in patients with various malignancies including gastric, colon, breast, and lung cancers (13
, 14)
. Most reports have associated the increased arginase activity with the need for malignant cells to produce polyamines to sustain their rapid proliferation (15)
. Recent in vitro models suggest that macrophages stimulated by interleukin (IL)4 and IL13 produce arginase I and can cause T-cell anergy by decreasing the expression of the T-cell receptor CD3 chain (16)
. Using mice bearing the Lewis lung carcinoma (3LL), we asked whether one or more of the enzymatic pathways that metabolize L-Arg were present in the tumor microenvironment and could explain the molecular alterations seen in T cells from patients with cancer. The results show that a unique subpopulation of mature tumor-associated myeloid cells but not tumor cells or immature myeloid cells express arginase I and cationic amino acid transporter 2B. Tumor-associated myeloid cells inhibit CD3 expression and antigen-specific T-cell responses. Inhibition of arginase in vivo decreased tumor growth in mice and, therefore, may represent a target for new therapies. High levels of arginase I and a decreased CD3 levels in the infiltrating T cells were also found in human non-small cell lung cancer samples.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Antibodies and Reagents.
CD3 and CD3
expression in murine T lymphocytes were measured by flow cytometry using anti-mouse-CD3-fluorescein isothiocyanate (FITC; PharMingen-Becton Dickinson, San Diego, CA) and anti-mouse-CD3-phycoerythrin (PE; Santa Cruz Biotechnology, Santa Cruz, CA). Human CD3 and CD3 expression was detected using anti-human CD3-PE and anti-human CD3-FITC (Beckman-Coulter, Miami, FL). Mouse IgG1-FITC-IgG2b-PE, rat IgG1-FITC, and rat-IgG2-PE (PharMingen-Becton Dickinson) were used as isotype controls. Antibodies against inducible nitric oxide synthase (Santa Cruz Biotechnology), murine arginase I (Transduction-Becton Dickinson, San Jose, CA), human arginase I (Santa Cruz Biotechnology), and arginase II (a kind gift of Dr. Sidney Morris Jr., University of Pittsburgh, Pittsburgh, PA) were used for Western blots. Other antibodies included anti-CD11b, CD16/CD32, I-A/I-E, H-2Db, CD80, CD86, CD45RB, CD40, CD11c, CD4, CD8a, CD14, B220, and CD49f labeled with FITC or PE (PharMingen-Becton Dickinson), anti-DEC-205 FITC, anti-CD68 FITC (Serotech, Raleigh, NC), and anti-F4/80 (Caltag, Burlingame, CA).
The specific arginase inhibitor N-hydroxy-nor-L-Arg (Calbiochem, San Diego, CA) was used to confirm the role of arginase in the loss of CD3 and CD3 in vitro. In addition, N-hydroxy-nor-L-Arg was injected s.c. in mice at 20 mg/kg/day, 40 mg/kg/day, and 80 mg/kg/day. Animals were also injected s.c. with L-Arg (500 mg/kg/day). Analogs of L-Arg symmetrical NG-NG-dimethyl-L-Arginine and N-nitro-L-Arg were purchased from Calbiochem and used at 1 mM. The amino acid L-Lysine (Sigma) was used at 1 mM.
Dichlorodihydrofluorescein diacetate (Molecular Probes, Eugene, OR) and dihydroethidium (Molecular Probes) were used to measure reactive oxygen species. Catalase (200 units/ml; Roche Diagnostics, Indianapolis, IN) was used to test the role of hydrogen peroxide in the down-regulation of CD3.
Cell Subset Isolation from 3LL Tumors.
Tumors were removed from mice under sterile conditions after 7, 14, and 21 days of tumor injection. Tumors were digested with trypsin-EDTA (Invitrogen) for 3 h, and the single cell suspension was passed through a 40-µm cell strainer (Becton Dickinson-Falcon, Franklin Lakes, NJ). Cells were then stained for CD11b, CD16, CD32, I-A/I-E, CD49f, CD4, CD8, or Gr-1 and separated into different subsets, as discussed in the "Results," using a Sorter Epics Altra (Beckman-Coulter) or anti-FITC and anti-PE immunomagnetic beads (Miltenyi Biotec, Auburn, CA). Purity of the subsets ranged between 93% and 99%. T cells were isolated from spleens of mice by T-cell enrichment columns (R&D Systems, Minneapolis, MN) according to the manufacturer’s specifications. T-cell purity (CD3+) ranged between 89% and 95%.
Cocultures in Transwells (Boyden Chambers).
Cell subpopulations isolated from 3LL tumors were cultured in the bottom chamber of a transwell (six-well plates) for 24 h using RPMI containing 150 µM L-Arg (physiological levels). In parallel, 1 x 106 normal splenic T cells were stimulated with 1 µg/ml anti-CD3 plus 500 ng/ml anti-CD28 (PharMingen-Becton Dickinson, San Diego, CA), in the absence of L-Arg for 24 h. The stimulated T cells were then cultured in the upper chamber of a transwell system, which has 0.4-µm pores (Falcon-Becton Dickinson). The expression of CD3 in the T cells was tested after 24, 48, and 72 h. Results were expressed as mean fluorescence intensity. In addition, T-cell proliferation was tested by [3H]thymidine incorporation.
Immunohistochemistry.
3LL tumors were fixed in buffered 10% formalin and embedded in paraffin. Serial 4 µm-thick sections were cut and mounted on poly-L-lysine coated Probe-On slides (Fisher Biotech). Tissue sections were heated overnight at 37°C, deparaffinized using xylene, and rehydrated in graded alcohol dilutions. Endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide solution. After washing, nonspecific binding was reduced by incubation in 1% normal goat serum diluted with PBS. Tissue sections were then incubated with anti-arginase I (Transduction, Becton Dickinson) or IgG mouse isotype control (Becton Dickinson) for 2 h at room temperature. After washing, slides were incubated with biotinylated goat anti-mouse antibody (1:200; Dako, Carpinteria, CA) for 30 min at room temperature. Thereafter, sections were rinsed and incubated with streptavidin-biotin-peroxidase complex (Strept-ABComplex; Dako) for 30 min at room temperature. Diaminobenzidine (Sigma-Aldrich, St. Louis, MO) was used as a chromogen and counterstained with hematoxylin.
Detection of Endocytotic Capacity and Nonspecific Esterases.
To further study the endocytotic pathway, 1 x 105 tumor-associated myeloid cells, non-tumor-associated myeloid cells and peritoneal macrophages were pulsed with FITC-labeled K-12 Escheria coli bioparticles (relation 1:200) using the Vybrant Phagocytosis Assay kit (Molecular Probes) following the vendor’s recommendations. Trypan blue was used as extracellular quenching probe. Non-specific esterases were measured in cytospins prepared from 3 x 105 tumor-associated myeloid cells, non-tumor-associated myeloid cells, and peritoneal macrophages using 
-naphthyl acetate esterase (Sigma-Aldrich).
Reactive Oxygen Species Detection.
Dyes sensitive to oxidation by reactive oxygen species were used to determine oxidative stress in cells isolated from 3LL tumors. Dichlorodihydrofluorescein diacetate (Molecular Probes) was used to test the production of hydrogen peroxide, peroxinitrites, and hydroxyl radical. Dihydroethidium (Molecular Probes) was used to test the production of superoxide anion. Cells were labeled for 5 min 37°C in RPMI 1640 using 2 µM of the respective dye, washed twice with RPMI 1640 and fluorescence determined by flow cytometry.
L-Arg Measurement and L-Arg Incorporation.
L-Arg concentration in tissue culture medium was measured by high-performance liquid chromatography with electron capture detection using an ESA-CoulArray Model 540 (ESA Inc., Chelmsford, MA) with an 80 x 3.2 column with 120A pore size. Briefly, supernatants were deproteinized in methanol. After centrifugation at 6000 x g for 10 min at 4°C, the supernatant was derivatized with 0.2 M O-phtaldialdehyde containing 7 mM ß-mercaptoethanol. Fifty microliters of the sample were injected into the column. The retention time for L-Arg was 10.2 min. Standards of L-Arg were prepared in methanol. [3H]L-Arg incorporation was measured at 3, 6, 12, and 24 h. One million cells isolated from 3LL tumors were cultured in RPMI 1640 containing 150 µM L-Arg and 5 µCi of [3H]L-Arg.
Northern Blot.
Two million cells were used for RNA extraction using lysis with TRIzol (Invitrogen) following the manufacturer’s specifications. Five micrograms of total RNA from each sample were electrophoresed under denaturing conditions, blotted onto nytran membranes (Schleicher & Schuell Inc, Keene, NH) and cross-linked by UV irradiation. Membranes were prehybridized at 42°C in ULTRAhyb buffer (Ambion, Austin, TX) and hybridized overnight with 1 x 106 cpm/ml of 32P-labeled probe. Probes for detection of arginase I, arginase II, cationic amino acid transporter 1, cationic amino acid transporter 2B, and glyceraldehyde-3-phosphate dehydrogenase (Clontech, Palo Alto, CA) mRNA were labeled by random priming using a RediPrime Kit (Amersham, Buckinghamshire, United Kingdom) and [-32P]dCTP (3,000 Ci/mmol; NEN Life Science Products, Boston, MA). Membranes were washed and subjected to autoradiography at –70°C using Kodak Biomax-MR films (Eastman Kodak, New Haven, CT) and intensifying screens.
Reverse Transcription-PCR.
Two micrograms of total RNA were treated with DNase I (Invitrogen) and converted to cDNA using SuperScript kit (Invitrogen), following the manufacturer’s specifications. PCR reactions using recombinant Taq polymerase (Invitrogen) were done to determine the expression of indoleamine 2, 3-dioxygenase (740 bp), cationic amino acid transporter 2A (115 bp), cationic amino acid transporter 2B (121 bp), and ß-actin (697 bp). The linearity of the PCRs was determined based on the volume of cDNA (2 µl) and the number of cycles: 30 for indoleamine 2, 3-dioxygenase and ß-actin, 31 for cationic amino acid transporter 2A, and 32 for cationic amino acid transporter 2B. The primers used were described previously (17
, 18)
: ß-actin, forward 5'-AGCAAGAGAGGTATCCTG-3', reverse 5'-CCTTACGGATGTCAACGTC-3'; indoleamine 2, 3-dioxygenase, forward 5'-GTACATCACCATGGCGTATG-3', reverse 5-GCTTTCGTCAAGTCTTCATTG-3'; and cationic amino acid transporter 2B, forward 5'-CCCAATGCCTCGTGTAATCTA-3' and reverse 5'-TGCCACTGCACCCGATGACAA-3'. Amplification products were run in 1.5% agarose gels, visualized by ethidium bromide (Sigma) and analyzed in a Gel-Doc instrument (Bio-Rad Laboratories).
Western Blots.
Cell extracts were obtained as described previously (16)
. The expression of arginase I, arginase II, and glyceraldehyde-3-phosphate dehydrogenase was detected by immunoblot using 30 µg of cell extracts. Cytoplasmic extracts were electrophoresed in 12% or 8% Tris-Glycine gels (Novex, San Diego, CA), transferred to polyvinylidene difluoride membranes, and immunoblotted with the appropriate antibodies. The reactions were detected using the enhanced chemiluminescence kit (Amersham).
Arginase Activity Assay.
Cell lysates (5 µg) from 3LL cells cultured in vitro, tumor-associated myeloid cells, and non-tumor-associated myeloid cells selections were tested for arginase activity by measuring the production of L-ornithine and urea. Briefly, cell lysates were added to 25 µl of Tris-HCl (50 mM; pH 7.5) containing 10 mM MnCl2. This mixture was heated at 55–60°C for 10 min to activate arginase. Then, a solution containing 150 µl carbonate buffer (100 mM; Sigma) and 50 µl L-Arg (100 mM) was added and incubated at 37°C for 20 min. The hydrolysis reaction from L-Arg to L-ornithine was identified by a colorimetric assay after the addition of ninhydrin solution and incubation at 95°C for 1 h. In addition, the hydrolysis reaction from L-Arg to urea was detected with diacetyl monoxime (Sigma) and incubation at 95°C for 10 min.
Statistical Analysis.
Comparisons of CD3 expression, L-Arg incorporation, L-Arg concentrations, arginase activity, and tumor volume were done with one way ANOVA test using the Graph Pad statistical program (Graph Pad, San Diego, CA).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Furthermore, high arginase activity, as measured by the conversion of L-Arg to ornithine and urea, was only present in the 3LL tumor single cell suspension (Fig. 1C
; P < 0.0001). Inducible nitric oxide synthase, the third enzymatic pathway metabolizing L-Arg, was not detectable in any of the cell preparations (data not shown). The cells producing arginase I in the tumor microenvironment were unknown, although prior reports have shown that some tumor cell lines and peritoneal macrophages can produce arginase in vitro (13, 14, 15)
. The 3LL cells expanded in vitro and used to generate the tumors in mice did not express arginase I, suggesting that either tumor cells developed the ability to produce arginase I after being injected into mice or that other cells infiltrating the tumor were producing arginase I. Immunohistochemistry done on day 14 tumor sections showed a significant number of arginase I-positive cells, which had a macrophage morphology, whereas tumor cells and infiltrating lymphocytes appeared to be negative (Fig. 2A)
. Analysis of cell markers in the single cell suspensions from the 3LL tumors showed the majority of the cells to be CD49f+ tumor cells (43.07% ± 1.56), infiltrating CD4+ or CD8+ T cells (11.91% ± 3.94), and CD11b+ myeloid cells (39.34% ± 4.23), with 
1% of the cells being CD56+ natural killer cells or CD19+ B cells. A very low expression of CD3 (CD3) was seen in the CD4+ and CD8+ T cells (data nor shown). In addition, a significant proportion of the CD11b+ myeloid cells were also positive for CD16+/CD32+ and I-A/I-E+ (data not shown). To further characterize the population producing arginase I, the single cell suspensions of 3LL tumors were stained and sorted into three distinct populations, tumor cells (CD49f+), myeloid cells (CD11b+, CD16/CD32+, and I-A/I-E+), and T cells expressing CD4+ or CD8+, which together accounted for >95% of the cells in the tumor preparations. As shown in Fig. 2B
, cells expressing CD11b, CD16/CD32, and I-A/I-E had the highest arginase activity as compared with tumor cells (CD49f+) or infiltrating T lymphocytes.
|
|
. The mature CD11b+, GR1– cells also expressed CD16/CD32, I-A/I-E, H-2Db, CD80, CD86, CD68, CD40, and CD45RB, and were negative for dendritic cell markers CD11c, B220, DEC-205, CD4, and CD8a, and for other myeloid cells markers such as CD14 and F4/80 (Fig. 2D)
. These cells will be referred from here on as tumor-associated myeloid cells. Tumor-associated myeloid cells stimulated with lipopolysaccharide or CD40L failed to further differentiate into CD11c+ dendritic cells (data not shown).
Arginase activity and expression was then tested in the unseparated single cell suspension, tumor-associated myeloid cells, and the remaining cells that mainly included tumor cells and infiltrating T cells and were labeled non-tumor-associated myeloid cells. Tumor-associated myeloid cells expressed high levels of protein and mRNA for arginase I and arginase II (Fig. 3, A and B)
and had a high arginase activity (Fig. 3C)
. In contrast, non-tumor-associated myeloid cells did not express arginase I and arginase II nor had arginase activity. Again, inducible nitric oxide synthase expression was not detected in the tumor-associated myeloid cell or non-tumor-associated myeloid cell populations (data not shown). Tumor-associated myeloid cells had a distinct morphology with an irregular cytoplasm and a high content of intracytoplasmic vacuoles (Fig. 3D
, top left), whereas the non-tumor-associated myeloid cells were negative for arginase I and included a mixture of tumor cells and infiltrating lymphocytes (Fig. 3D
, top right). Arginase I expression was additionally confirmed by immunohistochemistry, showing positive staining for arginase I in the tumor-associated myeloid cells (Fig. 3D
, bottom left, note that a contaminant lymphocyte is negative for arginase I) but not the nontumor-associated myeloid cells (Fig. 3D
, bottom right). Cytokine profiles by RNase protection assay of tumor-associated myeloid cells and non-tumor-associated myeloid cells demonstrated an increased expression of IL-10, IL-1, IL-1ß, IL-1RN, and IL-6 in the tumor-associated myeloid cells but not in the non-tumor-associated myeloid cells (data not shown). Enriched cell subpopulations were also tested for phagocytic ability and the production of esterases. Tumor-associated myeloid cells had a lower capacity to phagocytose FITC-labeled E. coli K-12 bioparticles than did control peritoneal macrophages (Fig. 4
, top), whereas non-tumor-associated myeloid cells had no phagocytic activity. In addition, 89% of tumor-associated myeloid cells were positive for non-specific esterases (Fig 4
, bottom), as compared with only 33% of the non-tumor-associated myeloid cells and 99% of the peritoneal macrophages.
|
|
and activity (Fig. 5B)
as early as day 7 after s.c. injection of the tumor cells, which continued increasing throughout the 21 days of tumor growth. The increasing activity was not caused by a higher percentage of tumor-associated myeloid cells infiltrating the tumor (Fig. 5C)
, suggesting instead an increase in arginase I activity on a per cell basis. Simultaneously, we tested the expression of CD3 and CD3 chains in T cells infiltrating the tumors, finding a major decrease by day 7 (Fig. 5, D and E)
. In contrast, splenic T cells from tumor-bearing mice only showed a detectable decrease in CD3 by day 14 and CD3 by day 21, which is in accordance with the original description by Mizoguchi et al. (21)
. Interestingly, little Arginase activity or cells with a tumor-associated myeloid cells phenotype were detected in the spleens of tumor bearing mice even by day 21 (data not shown).
|
, with cationic amino acid transporter 2B being preferentially expressed in the tumor-associated myeloid cells and cationic amino acid transporter 1 in the non-tumor-associated myeloid cells. The increased cationic amino acid transporter 2B expression was confirmed by reverse transcription-PCR using specific primers (Fig. 6B)
. Tumor-associated myeloid cells incorporated [3H]L-Arginine five times higher than the non-tumor-associated myeloid cells and approximately three times higher than the unseparated tumor single cell suspension, in the first 12–24 h of culture (Fig. 6C)
, resulting in a rapid depletion of L-Arg in the tissue culture medium (Fig. 6D)
. The addition of cationic amino acid transporter 2B inhibitors, symmetric dimethyl arginine and L-Lysine, decreased the L-Arg incorporation in the tumor-associated myeloid cell population to levels similar to the non-tumor-associated myeloid cells population (Fig. 6E)
. In contrast, the L-Arg analog, N-nitro-L-Arg, which is not transported by cationic amino acid transporter 2, did not affect L-Arg incorporation suggesting that cationic amino acid transporter 2B was mediating L-Arg transport into tumor-associated myeloid cells.
|
chain and induce T-cell dysfunction (22)
. To test this possibility purified tumor-associated myeloid cells and non-tumor-associated myeloid cells were labeled with dihydroethidium and dichlorodihydrofluorescein diacetate. Dihydroethidium is a marker of superoxide anion, whereas dichlorodihydrofluorescein diacetate is oxidized by hydrogen peroxide, peroxinitrites, and hydroxyl radicals. Freshly isolated enriched tumor-associated myeloid cells did not have detectable levels of reactive oxygen species (Fig. 7A)
as evidenced by the absence of fluorescence with dihydroethidium and dichlorodihydrofluorescein diacetate. However, stimulation with phorbol 12-myristate 13-acetate demonstrated their ability to produce reactive oxygen species. In contrast, non-tumor-associated myeloid cells displayed high accumulation of reactive oxygen species, even without additional stimulation by phorbol 12-myristate 13-acetate. Similarly, the production of indoleamine 2, 3-dioxygenase by dendritic cells has been reported as a mechanism that can inhibit T-cell proliferation (7)
. A low level of indoleamine 2, 3-dioxygenase expression was detected in the non-tumor-associated myeloid cell fraction (Fig. 7B)
, but not in the tumor-associated myeloid cell subpopulation. Thus, the data suggest that tumor-associated myeloid cells are a unique subset of mature myeloid cells that produce high levels of arginase I in the tumor microenvironment but not reactive oxygen species or indoleamine 2, 3-dioxygenase.
|
Expression and Antigen-Specific Proliferation of T Cells.. However, in the absence of L-Arg the re-expression of CD3 is blocked, preventing the assembly of new T-cell receptors on the cell membrane (16)
. Coculture of freshly isolated tumor-associated myeloid cells with T cells stimulated with anti-CD3 + anti-CD28 in transwells (Boyden Chambers) resulted in a similar effect with an inability of T cells to re-express CD3 and CD3 chains (Fig. 8, A and B)
. In contrast, nontumor-associated myeloid cells did not alter the normal cycling of CD3 and the CD3. This effect was prevented by the addition of the Arginase inhibitor N-hydroxy-nor-L-Arg or excess exogenous L-Arg (2 mM) into the culture but not by the addition of catalase, a hydrogen peroxide scavenger (Fig. 8, C and D)
, demonstrating that the depletion of L-Arg by tumor-associated myeloid cells caused the impaired T-cell receptor expression. Histograms of CD3 and CD3 expression in activated T cells cocultured with tumor-associated myeloid cells for 72 h confirmed the decreased expression of the T-cell receptor chains and their normal re-expression with the addition of the Arginase inhibitor N-hydroxy-nor-L-Arg (Fig. 8, E and F)
|
and OT-2 (Table 2)
proliferation to OVA peptides (P < 0.001). This suppressive effect of tumor-associated myeloid cells was prevented by the addition of arginase inhibitor N-hydroxy-nor-L-Arg or exogenous L-Arg. In contrast, OT-1 and OT-2 cells stimulated with OVA and cocultured with non-tumor-associated myeloid cells proliferated similarly to control cells.
|
|
as compared with the normal peripheral blood mononuclear cells. Furthermore, the CD3 chain expression in the infiltrating T cells was markedly decreased in patients as compared with T cells from normal controls (Fig. 9C)
. Unfortunately normal surrounding lung tissue was not available at the time.
|
, tumor growth on day 14 was significantly inhibited by N-hydroxy-nor-L-Arg in a dose-dependent manner. This anti-tumor effect was similar with the combination of N-hydroxy-nor-L-Arg plus L-Arg. In both treatments the anti-tumor effect was observed during the whole period of the experiment (Fig. 10B)
. In addition, the expression of arginase I was markedly decreased in the tumor-associated myeloid cells infiltrating the tumors of mice receiving N-hydroxy-nor-L-Arg (Fig. 10C)
.
|
, suggesting that the anti-tumor effect caused by the inhibition of arginase is in part dependent on lymphocyte function. |
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
expression and are unable to proliferate (10)
. More recently, Rodriguez et al. (16)
showed that murine peritoneal macrophages stimulated with T-helper 2 cytokines (IL-4 + IL-13) produce arginase I, rapidly reducing L-Arg concentration in the microenvironment and inducing T-cell dysfunction. In contrast, macrophages producing arginase II do not deplete L-Arg from the microenvironment and do not impair T-cell function. However, it was unclear whether these in vitro mechanisms were present in disease. An increased Arginase activity has been described in patients with different types of tumors (13 , 14) and has been associated with the need of malignant cells to produce polyamines to sustain their rapid proliferation (15) . However, the source of Arginase and its potential role as a mechanism for tumor evasion were unclear. The results shown here demonstrate that in the 3LL model a distinct subpopulation of tumor-infiltrating myeloid cells, and not tumor cells, produces high levels of arginase I and are potent inhibitors of T-cell receptor expression and antigen-specific T-cell responses. These cells have also been shown to be potent inducers of regulatory T cells (24) and, therefore, may represent a unique subpopulation with the ability to suppress the protective immune response through various mechanisms. Other cells within the tumor microenvironment including the malignant cells, T lymphocytes, and even other myeloid subpopulations did not produce arginase I and did not impair T-cell function in this tumor model. Furthermore, the almost complete inhibition of the suppressive function of tumor-associated myeloid cells by an Arginase inhibitor suggested that arginase I may represent one of the principal mechanisms used by these cells to impair T-cell function. Therefore, the increase in arginase I expression may not only facilitate tumor growth, but may also have as a secondary effect, the local reduction of L-Arg levels allowing tumors to escape the immune response.
Previous reports have suggested that Arginase activity in cancer patients might be coming from the tumor cells to sustain their rapid proliferation (15)
. However, our data evaluating multiple human lung carcinoma cell lines failed to demonstrate any Arginase activity or arginase I expression.6
Which signal(s) initiate the production of arginase I by the tumor-associated myeloid cells is still unclear. Murine peritoneal macrophages stimulated with IL-4 and IL-13 produce arginase I but not inducible nitric oxide synthase, whereas macrophages stimulated with interferon 
produce inducible nitric oxide synthase and not arginase I. However, initial studies of the 3LL cell line fail to show the production of either cytokine.6
Therefore, it is possible that T cells, which preferentially produce T-helper 2 cytokines in mice with progressively growing tumors (25)
, may initiate the production of arginase I by tumor-associated myeloid cells. The sequence of signals from tumor derived factors and cytokines from infiltrating T cells that initiate and sustain the production of arginase in tumor-associated myeloid cells remains to be fully understood.
How low do L-Arg levels need to be to alter CD3 chain expression and T-cell function, and can these levels occur in vivo? L-Arg levels in serum of normal individuals ranges from 50 µM to 150 µM. In vitro data show that concentrations below 40 µM cause the rapid decrease of CD3 chain in Jurkat cells and impair its re-expression in stimulated T cells.7
Consistent with this, rodents and patients with trauma or patients undergoing liver transplantation have a rapid decrease in circulating L-Arg levels to concentrations below 40 µM (26
, 27)
. This phenomenon is paralleled by poor T-cell function (27)
and, as shown recently by Ichihara et al. (28)
, with a decreased expression of CD3 chain. Additional experiments with transgenic mice that overexpress arginase I in enterocytes show a selective depletion of L-Arg in serum, concomitant with a poor thymic development (29)
. Preliminary experiments have shown large variations in the levels of L-Arg in the serum of tumor-bearing mice in the first 14 days after tumor implantation (data not shown). It is possible that serum levels of L-Arg fail to reflect the changes occurring within the tumor microenvironment.
Arginase activity, however, is not detected to a great extent in the tissue culture medium of the tumor-associated myeloid cells, suggesting that L-Arg incorporation could be the mechanism of L-Arg consumption. The cationic amino acid transporter system is characterized by its high affinity for basic amino acids, its independence from Na+, and the ability of substrate on the opposite (trans) side of the membrane to increase transport activity (30) . In accordance with these observations, tumor-associated myeloid cells, which express high levels of cationic amino acid transporter 2B and arginase I, have an increased incorporation of L-Arg and rapidly reduce extracellular concentration of L-Arg. In contrast, tumor cells and other lymphoid-infiltrating cells (non-tumor-associated myeloid cells), which express cationic amino acid transporter -1, do not.
Recent publications have suggested a close correlation between the availability of certain amino acids and the immune response. Munn et al. (7) described that tryptophan metabolism by macrophages producing indoleamine 2, 3-dioxygenase inhibits T-cell proliferation and sensitizes activated T cells to apoptosis (18) . Tumor-associated myeloid cells, however, did not express indoleamine 2, 3-dioxygenase, and there was only a low-level expression in the non-tumor-associated myeloid cell population. Several reports have also shown the presence of immature myeloid cells expressing CD11b+, GR-1+, F4/80+ in the spleen of tumor-bearing mice. These cells produce reactive oxygen species and low levels of arginase I, which can increase after stimulation with IL-4. These immature myeloid suppressor cell lines can impair alloreactivity in vitro through a nitric oxide-dependent mechanism (8 , 9 , 31) and induce T-cell apoptosis; however, they require cell-cell contact to impair T-cell function (8 , 31 , 32) . In contrast, the tumor-associated myeloid cell subpopulation reported here expresses mature myeloid markers, does not require cell to cell contact to inhibit T-cell activity (as shown in the transwell experiments), and does not cause T-cell apoptosis in cocultures (data not shown). Therefore, the CD11b+ tumor-associated myeloid cells producing arginase I may represent a unique subpopulation of potent suppressor cells within the tumor microenvironment.
How amino acid starvation impairs T-cell function is unclear. The absence of the essential amino acid leucine has been associated with an increase in the synthesis and stability of mRNA for CHOP (33)
. This gene encodes a transcription factor that interacts with CCAAT/enhancer-binding proteins family, which, in turn, may inhibit the normal proliferation of cells (34)
. Our data show that metabolism of the non-essential amino acid L-Arg may also control T-cell function through the modulation of CD3 expression. In Jurkat cells the decrease of CD3 appears to be caused by a decreased CD3 mRNA stability (10)
, associated with de novo synthesis of a protein that releases a ribonucleoprotein complex bound to the 3' untranslated region of CD3 mRNA.6
In normal human T cells, however, L-Arg starvation appears to alter CD3 re-expression by a specific decrease in CD3 translation.8
L-Arg starvation and accumulation of empty tRNA for L-Arg could induce the activation of GCN2, which phosphorylates eIF2 and inhibits the access of methionyl tRNA to the ribosome and, therefore, impairs the initiation of translation (35)
.
The injection of N-hydroxy-nor-L-Arg and N-hydroxy-nor-L-Arg plus L-Arg in tumor-bearing mice significantly inhibited tumor growth in a dose-dependent manner. This was associated with a lower expression of arginase I in the tumor-associated myeloid cells population but no changes in the percentage of these cells infiltrating the tumor. The effect of N-hydroxy-nor-L-Arg appears to be in part mediated by a lymphocyte response. Ongoing studies are aimed at additionally elucidating the anti-tumor mechanism of arginase inhibition.
Arginase I production alone is unlikely to be the only mechanism by which tumors impair T-cell function. Fas-Fas ligand interactions, the production of hydrogen peroxide, or indoleamine 2, 3-dioxygenase by macrophages or neutrophils may also play an important role in this process (3 , 36) . Additional studies will determine the relative contribution of each of these mechanisms in impairing T-cell function and possibly blocking the therapeutic potential of immunotherapy.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Requests for reprints: Augusto Ochoa, Stanley S. Scott Cancer Center, Louisiana State University, Health Sciences Center, 533 Bolivar Street, 455, New Orleans, LA 70112. Phone: (504) 599-0914; Fax: (504) 599-0864; E-mail: aochoa{at}lsuhsc.edu
6 P. Rodriguez, unpublished observations. 
7 P. Rodriguez and A. Zea, unpublished observations.
8 A. Zea, unpublished observations.
Received 2/11/04. Revised 4/30/04. Accepted 6/16/04.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. Ohta, A. Ohta, M. Madasu, R. Kini, M. Subramanian, N. Goel, and M. Sitkovsky A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments J. Immunol., November 1, 2009; 183(9): 5487 - 5493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Stewart, D. J. Liewehr, S. M. Steinberg, K. M. Greeneltch, and S. I. Abrams Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells J. Immunol., July 1, 2009; 183(1): 117 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Eruslanov, S. Kaliberov, I. Daurkin, L. Kaliberova, D. Buchsbaum, J. Vieweg, and S. Kusmartsev Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer J. Immunol., June 15, 2009; 182(12): 7548 - 7557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAGAVARAPU-CHARYULU, L. M. HERBERT, and D. M. LOPEZ Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors Anticancer Res, June 1, 2009; 29(6): 2051 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Torroella-Kouri, R. Silvera, D. Rodriguez, R. Caso, A. Shatry, S. Opiela, D. Ilkovitch, R. A. Schwendener, V. Iragavarapu-Charyulu, Y. Cardentey, et al. Identification of a Subpopulation of Macrophages in Mammary Tumor-Bearing Mice That Are Neither M1 nor M2 and Are Less Differentiated Cancer Res., June 1, 2009; 69(11): 4800 - 4809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Oberlies, C. Watzl, T. Giese, C. Luckner, P. Kropf, I. Muller, A. D. Ho, and M. Munder Regulation of NK Cell Function by Human Granulocyte Arginase J. Immunol., May 1, 2009; 182(9): 5259 - 5267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Norian, P. C. Rodriguez, L. A. O'Mara, J. Zabaleta, A. C. Ochoa, M. Cella, and P. M. Allen Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism Cancer Res., April 1, 2009; 69(7): 3086 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Rodriguez, M. S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, R. Sierra, and A. C. Ochoa Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes Cancer Res., February 15, 2009; 69(4): 1553 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-S. Choi, I. C. Martinez-Falero, C. Corset, M. Munder, M. Modolell, I. Muller, and P. Kropf Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages J. Leukoc. Biol., February 1, 2009; 85(2): 268 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Willimsky, M. Czeh, C. Loddenkemper, J. Gellermann, K. Schmidt, P. Wust, H. Stein, and T. Blankenstein Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness J. Exp. Med., July 7, 2008; 205(7): 1687 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor Cancer Res., July 1, 2008; 68(13): 5206 - 5215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Serafini, S. Mgebroff, K. Noonan, and I. Borrello Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells Cancer Res., July 1, 2008; 68(13): 5439 - 5449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kusmartsev, E. Eruslanov, H. Kubler, T. Tseng, Y. Sakai, Z. Su, S. Kaliberov, A. Heiser, C. Rosser, P. Dahm, et al. Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma J. Immunol., July 1, 2008; 181(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers Clin. Cancer Res., June 15, 2008; 14(12): 3966 - 3974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Negin, D. Panka, W. Wang, M. Siddiqui, N. Tawa, J. Mullen, S. Tahan, L. Mandato, A. Polivy, J. Mier, et al. Effect of Melanoma on Immune Function in the Regional Lymph Node Basin Clin. Cancer Res., February 1, 2008; 14(3): 654 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. F. Gajewski, E. A. Grimm, B. J. Nickoloff, and A. T. Weeraratna New Potential Therapeutic Targets in Melanoma ASCO Educational Book, January 1, 2008; 2008(1): 404 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S.-H. Chen Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function Blood, January 1, 2008; 111(1): 219 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O. Scumpia, M. J. Delano, K. M. Kelly-Scumpia, J. S. Weinstein, J. L. Wynn, R. D. Winfield, C. Xia, C. S. Chung, A. Ayala, M. A. Atkinson, et al. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis Blood, November 15, 2007; 110(10): 3673 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Talmadge Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5243 - 5248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinha, V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response J. Immunol., July 15, 2007; 179(2): 977 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani, and L. Rivoltini Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor-Based Antitumor Vaccine J. Clin. Oncol., June 20, 2007; 25(18): 2546 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Rodriguez, D. G. Quiceno, and A. C. Ochoa L-arginine availability regulates T-lymphocyte cell-cycle progression Blood, February 15, 2007; 109(4): 1568 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Ochoa, A. H. Zea, C. Hernandez, and P. C. Rodriguez Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 721s - 726s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev Reversal of Tumor-Mediated Immunosuppression Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function J. Exp. Med., November 27, 2006; 203(12): 2691 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Brown, C. Blank, J. Kline, A. K. Kacha, and T. F. Gajewski Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection J. Immunol., October 1, 2006; 177(7): 4521 - 4529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Ezernitchi, I. Vaknin, L. Cohen-Daniel, O. Levy, E. Manaster, A. Halabi, E. Pikarsky, L. Shapira, and M. Baniyash TCR {zeta} Down-Regulation under Chronic Inflammation Is Mediated by Myeloid Suppressor Cells Differentially Distributed between Various Lymphatic Organs J. Immunol., October 1, 2006; 177(7): 4763 - 4772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Munder, H. Schneider, C. Luckner, T. Giese, C.-D. Langhans, J. M. Fuentes, P. Kropf, I. Mueller, A. Kolb, M. Modolell, et al. Suppression of T-cell functions by human granulocyte arginase Blood, September 1, 2006; 108(5): 1627 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms. Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. McKenna and J. A. Kapp Accumulation of Immunosuppressive CD11b+ Myeloid Cells Correlates with the Failure to Prevent Tumor Growth in the Anterior Chamber of the Eye J. Immunol., August 1, 2006; 177(3): 1599 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Van Ginderachter, S. Meerschaut, Y. Liu, L. Brys, K. De Groeve, G. Hassanzadeh Ghassabeh, G. Raes, and P. De Baetselier Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer Blood, July 15, 2006; 108(2): 525 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kryczek, L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma J. Exp. Med., April 17, 2006; 203(4): 871 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin. Cancer Res., April 1, 2006; 12(7): 2359s - 2365s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P. Makarenkova, V. Bansal, B. M. Matta, L. A. Perez, and J. B. Ochoa CD11b+/Gr-1+ Myeloid Suppressor Cells Cause T Cell Dysfunction after Traumatic Stress J. Immunol., February 15, 2006; 176(4): 2085 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Haas, J. Sun, A. Vachani, A. F. Wallace, M. Silverberg, V. Kapoor, and S. M. Albelda Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine Clin. Cancer Res., January 1, 2006; 12(1): 214 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinha, V. K. Clements, and S. Ostrand-Rosenberg Interleukin-13-regulated M2 Macrophages in Combination with Myeloid Suppressor Cells Block Immune Surveillance against Metastasis Cancer Res., December 15, 2005; 65(24): 11743 - 11751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rutella, F. Zavala, S. Danese, H. Kared, and G. Leone Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance J. Immunol., December 1, 2005; 175(11): 7085 - 7091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-X. Wang, R. Li, G. Yang, M. Lim, A. O'Hara, Y. Chu, B. A. Fox, N. P. Restifo, W. J. Urba, and H.-M. Hu Interleukin-7-Dependent Expansion and Persistence of Melanoma-Specific T Cells in Lymphodepleted Mice Lead to Tumor Regression and Editing Cancer Res., November 15, 2005; 65(22): 10569 - 10577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Rodriguez, C. P. Hernandez, D. Quiceno, S. M. Dubinett, J. Zabaleta, J. B. Ochoa, J. Gilbert, and A. C. Ochoa Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma J. Exp. Med., October 3, 2005; 202(7): 931 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kusmartsev, S. Nagaraj, and D. I. Gabrilovich Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells J. Immunol., October 1, 2005; 175(7): 4583 - 4592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Pos, G. Safrany, K. Muller, S. Toth, A. Falus, and H. Hegyesi Phenotypic Profiling of Engineered Mouse Melanomas with Manipulated Histamine Production Identifies Histamine H2 Receptor and Rho-C as Histamine-Regulated Melanoma Progression Markers Cancer Res., May 15, 2005; 65(10): 4458 - 4466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. L. Vissers, C. H. Dejong, Y. C Luiking, K. C. Fearon, M. F von Meyenfeldt, and N. E. Deutz Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1142 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bronte, T. Kasic, G. Gri, K. Gallana, G. Borsellino, I. Marigo, L. Battistini, M. Iafrate, T. Prayer-Galetti, F. Pagano, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers J. Exp. Med., April 18, 2005; 201(8): 1257 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Zea, P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, et al. Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion Cancer Res., April 15, 2005; 65(8): 3044 - 3048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kusmartsev and D. I. Gabrilovich STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion J. Immunol., April 15, 2005; 174(8): 4880 - 4891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. De Santo, P. Serafini, I. Marigo, L. Dolcetti, M. Bolla, P. Del Soldato, C. Melani, C. Guiducci, M. P. Colombo, M. Iezzi, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination PNAS, March 15, 2005; 102(11): 4185 - 4190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinha, V. K. Clements, and S. Ostrand-Rosenberg Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease J. Immunol., January 15, 2005; 174(2): 636 - 645. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
